康哲药业2024H1点评：集采影响基本出清，创新转型稳步推进

研究报告 Research Report 19 Aug 2024 康哲药业 China Medical System Holdings (867 HK) 康哲药业 2024H1 点评：集采影响基本出清，创新转型稳步推进 The impact of centralized procurement has largely cleared, and innovation transformation is steadily progressing [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$7.23 | | 目标价 | HK$9.96 | | HTI ESG | 2.0-2.5-4.0 | E-S-G: 0-5, (Please refer to the ...